Flexible Lifestyles for Youth (FL3X) behavioural intervention for at-risk adolescents with Type 1 diabetes: a randomized pilot and feasibility trial.
Flexible Lifestyles for Youth (FL3X) behavioural intervention for at-risk adolescents with Type 1 diabetes: a randomized pilot and feasibility trial.
复制标题
针对患有 1 型糖尿病的高危青少年的灵活的青少年生活方式 (FL3X) 行为干预：一项随机试点和可行性试验。
DOI：
10.1111/dme.12641
复制
发表时间：
2015
期刊：
影响因子：
--
通讯作者：
Wysocki,T
中科院分区：
文献类型：
--
作者：
Mayer-Davis,EJ;Seid,M;Crandell,J;Dolan,L;Lagarde,WH;Letourneau,L;Maahs,DM;Marcovina,S;Nachreiner,J;Standiford,D;Thomas,J;Wysocki,T
目的确定青少年灵活生活方式（FL3X）行为干预改善1型糖尿病高危青少年血糖控制（HbA1c）和生活质量的潜在效应大小。MethodsParticipants [n = 61;年龄12-16岁，HbA1c64-119 mmol/mol(8-13%)]随机分为FL3X组（最少3次疗程）或常规治疗组。计算效应量（Cohen’s d），比较各组之间的平均差异。研究保留率（95%）、干预课程出勤率（87%参加了所有三个课程）和可接受性都很高（100%的青少年和91%的家长会向他人推荐该课程）。总体而言，干预组中41%的参与者和对照组中24%的参与者是“应答者”[hba1降低了0.6 mmol/mol (0.5%)；d = 0.37]。与对照组相比，干预组的hba1水平下降（d =‐0.18），糖尿病特异性生活质量增加（d = 0.29），但一般生活质量下降（d =‐0.23）。结论FL3X项目值得进一步研究，以改善青少年1型糖尿病患者的hba1和糖尿病特异性生活质量。(临床试验注册编号：: NCT01286350)。
AimTo determine the potential effect sizes for the Flexible Lifestyle for Youth (FL3X) behavioural intervention to improve glycaemic control (HbA1c) and quality of life for at‐risk adolescents with Type 1 diabetes.MethodsParticipants [n=61; age 12–16 years, HbA1c64–119 mmol/mol (8–13%)] were randomized to FL3X (minimum three sessions) or usual care. Effect sizes (Cohen's d), comparing the mean difference between the groups, were calculated.ResultsStudy retention (95%), attendance at intervention sessions (87% attended all three sessions) and acceptability were high (100% of the adolescents and 91% of parents would recommend the programme to others). Overall, 41% of participants in the intervention group and 24% of participants in the control group were ‘responders’ [HbA1cdecreased by > 6 mmol/mol (0.5%); d = 0.37]. HbA1clevels decreased (d = ‐0.18), diabetes‐specific quality of life increased (d = 0.29), but generic quality of life decreased (d = ‐0.23) in the intervention compared with the control group.ConclusionsThe FL3X programme merits further study for improving HbA1cand diabetes‐specific quality of life in adolescents with Type 1 diabetes. (Clinical trials registry no.: NCT01286350).